"Bio Innovation: Accessibility Is as Important as Technology... Korea Leads the Way"
Jeremy Farrar of WHO Delivers Keynote at GBC
Highlights Basic Science, Patient Capital, and Regulatory Harmonization
A senior official from the World Health Organization (WHO) emphasized that ensuring the achievements of bio-innovation are broadly accessible to more people is a critical challenge for global health. With regard to South Korea, he assessed the country as a notable example for others, having built a bio-innovation ecosystem connecting science, industry, and the public sector.
Jeremy Farrar, Deputy Director-General of the WHO, stated during his keynote address at the '2026 Global Bio Conference (GBC)' held at the Grand InterContinental Parnas in Gangnam-gu, Seoul, on the 26th, that "accelerating innovation while ensuring that such innovation reaches as many people as possible is now an extremely important challenge."
Deputy Director-General Farrar emphasized that scientific and technological progress should not only benefit certain countries or specific social classes. He said, "If scientists are left to work solely for a small number of people in a small number of countries, inequality will intensify in the future," adding, "I believe that as inequality grows, so too will conflict."
Jeremy Farrar, Deputy Director-General of the World Health Organization (WHO), is giving a lecture on the theme "Era of Change: The Future of Global Health" at the 2026 Global Bio Conference (GBC) held on the 26th at the Grand Intercontinental Parnas in Gangnam-gu, Seoul. Photo by Seongmin Lee
View original imageHe gave high praise to Korea's capacity for bio-innovation. Deputy Director-General Farrar remarked, "Over the past 30 to 40 years, Korea has built a model for scaling up innovation by connecting academia, public and private institutions, and the education system with industry, centered around universities," adding, "Close cooperation between academia and industry is essential to turn research-stage ideas into actual products and production."
He continued, "The advance of science—from life sciences to artificial intelligence (AI) and digital technology—is at an astonishing level. What is now needed is to learn how to bring these great ideas and science to as many people as possible." He further stated, "Korea is at the vanguard. Other countries are both envious of Korea and eager to learn from its example."
As a prerequisite for ensuring the achievements of innovation reach patients, he pointed to long-term investment in basic science. Deputy Director-General Farrar explained, "The mRNA (messenger ribonucleic acid) vaccines during the COVID-19 pandemic were not the result of just 12 months of research," and added, "The great innovations we have experienced over the past 20 to 40 years were made possible because nations and industries invested in basic science, even when they didn't necessarily know where that science would lead."
He asserted that the so-called 'Valley of Death'—the gap between research outcomes and industrialization—requires the active roles of government and capital markets to bridge it. Developing new drugs or vaccines can take between 10 and 20 years before ideas are fully developed into products and delivered to patients. "Patient capital," which can support long-term investment, is crucial for fostering an innovation ecosystem. Deputy Director-General Farrar said, "I am not certain that governments are necessarily the best suited to take on direct risk, but they can create environments in which other stakeholders are encouraged to assume such risks."
He also identified regulatory harmonization between countries as a core assignment to enhance access to innovation. The WHO should connect national regulatory agencies such as the United States Food and Drug Administration (FDA), Korea’s regulatory authorities, and the European Medicines Agency (EMA) to lower regulatory barriers and allow innovative products to reach larger markets. He explained that as the market expands, more patients will gain access and there will also be positive effects in terms of pricing.
He further observed that the targets of bio and healthcare innovation must adapt to demographic shifts. According to him, demographic changes underway in Asia and Europe, including Korea, will have a profound impact on science, R&D, and healthcare services as a whole. He forecast, "For the next 10, 15, and 20 years, the focus of innovation will need to shift toward the elderly population."
Oh Yukyung, Commissioner of the Ministry of Food and Drug Safety, is speaking at the opening ceremony of the '2026 Global Bio Conference (GBC)' held on the 26th at the Grand InterContinental Parnas in Gangnam-gu, Seoul. Ministry of Food and Drug Safety
View original imageMeanwhile, marking its 12th year, the Global Bio Conference (GBC) is an annual event that brings together over 5,000 participants, including regulatory authorities in the global biopharmaceutical sector, pharmaceutical and biotechnology industry professionals, and academic experts, to share the latest technologies, industry trends, and regulatory policies in biopharmaceuticals. At the keynote session that day, in addition to Deputy Director-General Farrar, participants included Lee Sangyeop, Professor at KAIST; Azad Bonni, Global Head of Neuroscience and Rare Diseases at Roche; and David Nogales, Global Head of Technology Strategy at Merck KGaA, Germany.
Hot Picks Today
"Two Spend 500,000 Won in a Flash, Yet Wait Two Hours?" ... 'Dreamland' Shunned by Kids and Foreign Tourists
- The Era of Getting 200 Million Won After 30 Years Is Over... A Japanese Bank's "Perpetual Department Head" Who Just Clocked In Cries Out
- Spain Hit by Its Worst Tragedy... Lee Kangin, Moreno and Real Madrid Join Soccer World in Mourning
- They Said, “Make It Your Home for Life” - Then Suddenly Kicked 200 Passengers Off... What Happened to the Around-the-World Cruise?
- "130 Rice Bowls Sold Out in a Day"... 'Unfiltered Face' Adds 8 Million Won to Night Market Sales: China's Bungeunwoo
Oh Yukyung, Commissioner of the Ministry of Food and Drug Safety, said, "The bioindustry is a field in which innovative technologies are constantly emerging, rapidly growing as a driving force for future growth. Now, the speed at which the potential of innovation is connected to real-world results is what determines competitiveness," adding, "The Ministry will strongly support the innovation and global market expansion of K-Bio through science-based regulatory innovation and proactive global regulatory cooperation."
© The Asia Business Daily. All rights reserved. Unauthorized AI training and use prohibited.